Cartesian Therapeutics (RNAC)

Its platform introduces mRNA into cells so that they temporarily express therapeutic proteins. This differs from many traditional cell-therapy approaches that rely on DNA-based engineering, because mRNA naturally breaks down over time and does not integrate into the genome. The temporary nature of expression may offer advantages in diseases where controlled or repeatable immune modulation is desirable, although the clinical profile of each therapy must be established through trials.

Cartesian’s strategy focuses on autoimmune conditions, where the immune system mistakenly attacks the body’s own tissues. Cell therapy has historically been associated with oncology, particularly blood cancers, but the same broad field is increasingly being explored for immune-mediated diseases. By targeting autoimmune disorders, Cartesian seeks to extend advanced cell-based medicine into areas with chronic disease burden and significant unmet need.

The company’s work sits at the intersection of immunology, RNA science and cell manufacturing. Its manufacturing platform is an important part of the business because cell therapies require specialised processes for preparing, modifying and delivering living cells in a reproducible way. As a clinical-stage company, Cartesian Therapeutics is primarily evaluated on the progress of its pipeline, clinical data, safety findings, regulatory interactions and ability to scale manufacturing. Its distinctive proposition is the use of mRNA-engineered cell therapy as a potentially controllable and non-integrating approach to treating autoimmune disease.